Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Na⟨ve to Antiretroviral Therapy

被引:9
作者
Antinori, A. [1 ]
Ammassari, A. [1 ]
Torti, C. [2 ]
Marconi, P. [1 ]
Andreoni, M. [3 ]
Angarano, G. [4 ]
Bonora, S. [5 ]
Castagna, A. [6 ]
Cauda, R. [7 ]
Clerici, M.
Monforte, A. d'Arminio
De Luca, A. [7 ]
Di Perri, G. [5 ]
Galli, M. [8 ]
Girardi, E. [1 ]
Gori, A. [9 ]
Lazzarin, A. [6 ]
Lo Caputo, S. [10 ]
Mazzotta, F. [10 ]
Montella, F. [11 ]
Mussini, C. [12 ]
Perno, C. F. [3 ]
Puoti, M. [2 ]
Rizzardini, G.
Rusconi, S. [8 ]
Vullo, V. [13 ]
Carosi, G. [2 ]
机构
[1] Ist Nazl Malattie Infett Lazzaro Spallanzani IRCC, I-00149 Rome, Italy
[2] Univ Brescia, Clin Malattie Infett & Trop, Brescia, Italy
[3] Univ Roma Tor Vergata, Rome, Italy
[4] Univ Foggia, Foggia, Italy
[5] Univ Turin, Osped Amedeo di Savoia, Turin, Italy
[6] Univ Vita & Salute, Milan, Italy
[7] Univ Cattolica Sacro Cuore, Rome, Italy
[8] Univ Milan, Osped L Sacco, Milan, Italy
[9] Univ Milano Bicocca, Osped S Gerardo, Monza, Italy
[10] Osped SM Annunziata, Florence, Italy
[11] Osped S Giovanni Addolorata, Rome, Italy
[12] Univ Modena, Policlin Univ, I-41100 Modena, Italy
[13] Univ Roma La Sapienza, Rome, Italy
关键词
AIDS-RELATED MALIGNANCIES; LONG-TERM SAFETY; SECONDARY PROPHYLAXIS; CYTOMEGALOVIRUS RETINITIS; INITIAL RESPONSE; IMMUNE RECOVERY; LATE DIAGNOSIS; NAIVE PATIENTS; RISK-FACTORS; DISCONTINUATION;
D O I
10.1007/s15010-008-8134-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Individuals with advanced HIV infection na < ve to antiretroviral therapy represent a special population of patients frequently encountered in clinical practice. They are at high risk of disease progression and death, and their viroimmunologic response following the initiation of highly active antiretroviral therapy may be more incomplete or slower than that of other patients. Infection management in such patients can also be complicated by underlying conditions, comorbidities, and the need for concomitant medications. To provide practical guidelines to those clinicians providing care to HIV-infected patients in terms of diagnostic assessment, monitoring, and treatment. The principals of antiretroviral treatment in asymptomatic na < ve patients with advanced HIV infection are the same as those applicable to the general population with asymptomatic HIV infection. Na < ve patients with advanced HIV infection and a history of AIDS-defining illnesses urgently need antiretroviral treatment, with the choice of antiretroviral regimen and timetable based on such factors as concomitant treatment and prophylaxis, drug interactions, and potential concomitant drug toxicity. Finally, an adequate counseling program - both before and after HIV-testing - that includes aspects other than treatment adherence monitoring is a crucial step in disease management.
引用
收藏
页码:270 / 282
页数:13
相关论文
共 79 条
[1]   Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: Different patterns of phenotypic resistance in CSF and plasma [J].
Antinori, A ;
Perno, CF ;
Giancola, ML ;
Forbici, F ;
Ippolito, G ;
Hoetelmans, RM ;
Piscitelli, SC .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (12) :1787-1793
[2]  
Antinori A, 2004, ANTIVIR THER, V9, P291
[3]   Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy [J].
Antinori, A ;
Larussa, D ;
Cingolani, A ;
Lorenzini, P ;
Bossolasco, S ;
Finazzi, MG ;
Bongiovanni, M ;
Guaraldi, G ;
Grisetti, S ;
Vigo, B ;
Gigli, B ;
Mariano, A ;
Dalle Nogare, ER ;
De Marco, M ;
Moretti, F ;
Corsi, P ;
Abrescia, N ;
Rellecati, P ;
Castagna, A ;
Mussini, C ;
Ammassari, A ;
Cinque, P ;
Monforte, AD .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (11) :1681-1691
[4]   Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy [J].
Antinori, A ;
Cingolani, A ;
Alba, L ;
Ammassari, A ;
Serraino, D ;
Ciancio, BC ;
Palmieri, F ;
De Luca, A ;
Larocca, LM ;
Ruco, L ;
Ippolito, G ;
Cauda, R .
AIDS, 2001, 15 (12) :1483-1491
[5]   Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-Naive HIV-Infected individuals [J].
Antonucci, G ;
Girardi, E ;
Cozzi-Lepri, A ;
Capobianchi, MR ;
De Luca, A ;
Puoti, M ;
Petrelli, E ;
Carnevale, G ;
Rizzardini, G ;
Grossi, PA ;
Viganò, P ;
Moioli, MC ;
Carletti, F ;
Solmone, M ;
Ippolito, G ;
Monforte, AD .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (12) :E101-E109
[6]   Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness [J].
Bangsberg, DR ;
Acosta, EP ;
Gupta, R ;
Guzman, D ;
Riley, ED ;
Harrigan, PR ;
Parkin, N ;
Deeks, SG .
AIDS, 2006, 20 (02) :223-231
[7]   Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides [J].
Barreiro, P ;
Soriano, V ;
Casas, E ;
González-Lahoz, J .
AIDS, 2002, 16 (02) :245-249
[8]  
Benson Constance A., 2004, Morbidity and Mortality Weekly Report, V53, P1
[9]   Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy [J].
Berenguer, J ;
González, J ;
Pulido, F ;
Padilla, B ;
Casado, JL ;
Rubio, R ;
Arribas, JR .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (03) :394-397
[10]   Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012) [J].
Boyd, Mark A. ;
Dixit, Narendra M. ;
Siangphoe, Umaporn ;
Buss, Neil E. ;
Salgo, Miklos P. ;
Lange, Joep M. A. ;
Phanuphak, Praphan ;
Cooper, David A. ;
Perelson, Alan S. ;
Ruxrungtham, Kiat .
JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (09) :1319-1322